Search Results
Jan 22, 2026, 12:30 ET Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
represents an important validation of the trial findings and highlights the significance of chronic cough in patients with IPF," said James Cassella, PhD, Chief Development Officer of Trevi Therapeutics. "The statistically-significant reduction in 24-hour objective cough frequency across all dose groups
More news about: Trevi Therapeutics, Inc.
Jan 22, 2026, 11:12 ET Replacing Microbiota Makes Aging Intestines Young Again
studySeveral other Cincinnati Children's experts collaborated on this study, including first author Kodandaramireddy Nalapareddy, PhD, David Haslam, MD, and Theresa Alenghat, VMD, PhD. The Research Flow Cytometry Facility and the Comprehensive Mouse and Cancer Core at Cincinnati Children's also contributed
More news about: Cincinnati Children's Hospital Medical Center
Jan 22, 2026, 11:05 ET PhaseV Demonstrates How AI-Driven Site Selection and Real-Time Analytics Reduce Recruitment Uncertainty and Accelerate IBD Clinical Trials
for complex IBD studies."Our solution shifts clinical operations from reactive monitoring to dynamic trial optimization," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "By applying causal ML to granular patient- and site-level data, we allow sponsors to treat every covariate as an operational
More news about: PhaseV
Jan 22, 2026, 09:37 ET Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
Mistral) to reason in medicinal chemistry, biology, and clinical development with the precision required in modern pharma R&D.Alex Zhavoronkov, PhD, founder, CEO and CBO of Insilico Medicine invites pharma and biotech companies, AI labs, and cloud providers to "bring your AI model to Science MMAI
More news about: Insilico Medicine
Jan 22, 2026, 08:30 ET Israel Cancer Research Fund and Cancer Research Institute Announce Co-Funding of Grant to Address Immunotherapy Resistance in Melanoma
Research led by Asaf Madi, PhD, of Tel Aviv University could make TIL therapy more reliable and durable for patients with advanced diseaseNEW YORK, Jan. 22, 2026 /PRNewswire/ -- Israel Cancer Research
More news about: Israel Cancer Research Fund
Jan 22, 2026, 08:00 ET The Brain Aneurysm Foundation Highlights Recent Advances from its Research Grantees
aneurysms in the general population, we are still in the very early stages."Recent Highlights from Grant Recipients:Devin McBride, PhD, UTHealth Houston: BAF funding helped Dr. McBride generate preliminary data, leading to an NIH grant to expand research on the roles of platelets
More news about: Brain Aneurysm Foundation
Jan 22, 2026, 08:00 ET Target ALS Launches New Website to Democratize ALS Research and Better Serve the Global ALS Community
accessibility, usability, and inclusion were central to the design."ALS research moves fastest when barriers are removed," said Manish Raisinghani, MBBS, PhD, CEO of Target ALS. "This website is not just a visual refresh. It is infrastructure. It reflects how we work, who we serve, and our commitment to building
More news about: Target ALS
Jan 22, 2026, 08:00 ET Really Great Reading Earns Utah Tier I Recommendation to Expand Evidence-Based Literacy Instruction Statewide
PhD Science®, and
More news about: Really Great Reading
Jan 22, 2026, 07:50 ET "BE BOLD & GLOBAL": BE International Raih Prestasi Gemilang di Ajang Functional Foods for Wellness Awards 2026
IP-PA1, ekstrak gandum hasil fermentasi yang telah dipatenkan. Bahan ini telah diteliti secara lengkap oleh Prof. Hiroyuki Inagawa, PhD. Proses pengembangannya melalui metode budidaya khusus yang dipatenkan di lebih dari 10 negara.Dikombinasikan dengan Beta-glucan
More news about: BE International
Jan 22, 2026, 07:00 ET PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader
PT0511."Completing this Series B extension and dosing the first patient in our PT0511 Phase 1 study represent important milestones for PAQ," said Nan Ji, PhD, Chief Executive Officer of PAQ Therapeutics. "Together, these achievements highlight our continued execution against a multi-program clinical strategy
More news about: PAQ Therapeutics
Jan 22, 2026, 06:00 ET Allelica Licenses University of Cambridge BOADICEA Model to Deliver Comprehensive Breast Cancer Risk Assessment
assessment requires the integration of monogenic and polygenic genetic variation alongside established clinical risk factors," said Giordano Botta, PhD, CEO and Co-Founder of Allelica. "This license allows us to combine validated monogenic and polygenic risk, and clinical factors into a unified framework
More news about: Allelica, Inc.
Jan 22, 2026, 06:00 ET PhotonPharma Inc. Appoints Vaccine Innovation Leader William Warren, Ph.D. to Board of Directors
multimedia:https://www.prnewswire.com/news-releases/photonpharma-inc-appoints-vaccine-innovation-leader-william-warren-phd-to-board-of-directors-302667466.htmlSOURCE
More news about: PhotonPharma Inc.
Jan 21, 2026, 23:17 ET Inaugural Cures Conference to be held on Thursday, February 5, 2026 in NYC
tech.Dr. Edward Neilan MD, PhDDr. Edward "Ed" Neilan is the Chief Medical and Scientific Officer of the National Organization for Rare Disorders (NORD®). Ed is a physician-scientist and rare disease expert.Dr. Shoshana Shendelman PhD
More news about: DMA United
Jan 21, 2026, 17:17 ET The Inner Circle acknowledges Ruth L. Miller, PhD, DD, as a Pinnacle Professional Member Inner Circle of Excellence
Prominently featured in The Inner Circle, Ruth L. Miller, PhD, DD is recognized as a Pinnacle Professional Member Inner Circle of Excellence for her contributions as a Systems Scientist and Futurist advancing Consciousness Studies. Ruth L. Miller, PhD, DD, is a systems scientist and futurist who has been
More news about: The Inner Circle
Jan 21, 2026, 15:15 ET ParagonCorp Celebrates 40 Years: Reinforces Commitment as Purposeful Beauty Tech Company on Global Stage
Cross-sector leaders sharing their perspectives include: Retno Marsudi – Board of Council of Paragon Wardah, Stewardship for Global Impact, Davide Pennino, PhD – Co-Founder and CEO of Biotix, and Bhavna Rawlley – Managing Director of Accenture SEA.These forums address strategic issues ranging from the
More news about: ParagonCorp
Jan 21, 2026, 11:21 ET Misuse of AI chatbots tops annual list of health technology hazards
chatbots are powerful tools, the algorithms cannot replace the expertise, education, and experience of medical professionals," said Marcus Schabacker, MD, PhD, president and chief executive officer of ECRI. "Realizing AI's promise while protecting people requires disciplined oversight, detailed guidelines,
More news about: ECRI
Jan 21, 2026, 09:23 ET SONOMOTION ANNOUNCES FDA CLEARANCE FOR ITS BREAK WAVE™ LITHOTRIPSY DEVICE FOR TREATMENT OF KIDNEY STONES
clearance is a pivotal milestone for our company and, more importantly, for patients seeking better options for kidney stone treatment," said Oren Levy, PhD, Co-Founder and Chief Executive Officer of SonoMotion. "This 510(k) clearance represents a significant step toward commercialization, and we look forward
More news about: SonoMotion, Inc.
Jan 21, 2026, 09:05 ET Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-founder-and-ceo-steven-quay-md-phd-named-one-of-the-top-50-healthcare-technology-ceos-of-2025-302666789.htmlSOURCE
More news about: Atossa Therapeutics Inc
Jan 21, 2026, 09:00 ET Dr. Jourdan Holder Joins Hearts for Hearing as Senior Director of Audiology and Research
Jan. 21, 2026 /PRNewswire/ -- Hearts for Hearing is thrilled to announce the appointment of Jourdan Holder, Au.D., PhD, as Senior Director of Audiology and Research. In this newly created leadership role, Holder will provide clinical and research leadership across audiology
More news about: Hearts for Hearing
Jan 21, 2026, 09:00 ET Fourth Annual Study Finds AI Confidence Outpaces Readiness as Data Integrity Gaps Persist
area, it's about the need for professionals who can operate across data, business strategy, and AI governance simultaneously," said Murugan Anandarajan, PhD, Professor and Academic Director at Drexel LeBow's Center for Applied AI and Business Analytics. "That reality has major implications for how organizations
More news about: Precisely Software Limited
Jan 21, 2026, 09:00 ET Fourth Annual Study Finds AI Confidence Outpaces Readiness as Data Integrity Gaps Persist
area, it's about the need for professionals who can operate across data, business strategy, and AI governance simultaneously," said Murugan Anandarajan, PhD, Professor and Academic Director at Drexel LeBow's Center for Applied AI and Business Analytics. "That reality has major implications for how organizations
More news about: Precisely Software Limited
Jan 21, 2026, 09:00 ET Vierte jährliche Studie: Vertrauen in KI wächst schneller als Einsatzbereitschaft - Defizite bei Datenintegrität bleiben bestehen
Bedarf an Fachkräften, die gleichzeitig in den Bereichen Daten, Geschäftsstrategie und KI-Governance tätig sein können", sagte Murugan Anandarajan, PhD, Professor und akademischer Direktor am Drexel LeBow Center for Applied AI and Business Analytics. „Diese Tatsache hat erhebliche Auswirkungen darauf,
More news about: Precisely Software Limited
Jan 21, 2026, 09:00 ET Selon la quatrième étude de Precisely et LeBow, la confiance dans l'IA dépasse le niveau de préparation, alors que les lacunes en matière d'intégrité des données persistent
capables d'opérer simultanément dans les domaines des données, de la stratégie d'entreprise et de la gouvernance de l'IA, affirme Murugan Anandarajan, PhD, Professor and Academic Director au Center for Applied AI and Business Analytics du LeBow College of Business de l'université Drexel. Cette réalité
More news about: Precisely Software Limited
Jan 21, 2026, 08:44 ET IMAGE Skincare Welcomes Back Co-Founder Dr. Marc Ronert as Chief Executive Officer
2026 /PRNewswire/ -- IMAGE Skincare, the globally recognized professional skincare brand, announced today the return of Dr. Marc Ronert, MD, PhD, as Chief Executive Officer. A European board-certified plastic surgeon and co-founder of IMAGE Skincare, Dr. Ronert steps into the CEO role
More news about: IMAGE Skincare
Jan 21, 2026, 08:30 ET CereVasc Completes Enrollment of ETCHES Study of the eShunt® System for the Treatment of Communicating Hydrocephalus
device concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon and Chair Emeritus of Neurosurgery, and Adel Malek, MD, PhD, Chief of Neurovascular Surgery and Director of Cerebrovascular and Endovascular Neurosurgery. The patented eShunt System includes an endovascularly
More news about: CereVasc